SE9702401D0 - Pharmaceutical use - Google Patents

Pharmaceutical use

Info

Publication number
SE9702401D0
SE9702401D0 SE9702401A SE9702401A SE9702401D0 SE 9702401 D0 SE9702401 D0 SE 9702401D0 SE 9702401 A SE9702401 A SE 9702401A SE 9702401 A SE9702401 A SE 9702401A SE 9702401 D0 SE9702401 D0 SE 9702401D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical use
parathyroid hormone
osteoporosis
medicament
year
Prior art date
Application number
SE9702401A
Other languages
English (en)
Swedish (sv)
Inventor
Sverker Ljunghall
Sven Sjoegren
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9702401A priority Critical patent/SE9702401D0/xx
Publication of SE9702401D0 publication Critical patent/SE9702401D0/xx
Priority to AT98929965T priority patent/ATE275419T1/de
Priority to CA2294101A priority patent/CA2294101C/en
Priority to ES04017622T priority patent/ES2335404T3/es
Priority to DK98929965T priority patent/DK1001802T3/da
Priority to EP04017622A priority patent/EP1473040B1/de
Priority to ZA984947A priority patent/ZA984947B/xx
Priority to PT04017622T priority patent/PT1473040E/pt
Priority to AU79458/98A priority patent/AU753477B2/en
Priority to CA2698626A priority patent/CA2698626C/en
Priority to PT98929965T priority patent/PT1001802E/pt
Priority to AT04017622T priority patent/ATE447410T1/de
Priority to US09/125,247 priority patent/US6284730B1/en
Priority to DE69841279T priority patent/DE69841279D1/de
Priority to PCT/SE1998/001095 priority patent/WO1998057656A1/en
Priority to JP50425999A priority patent/JP4989811B2/ja
Priority to DK04017622.4T priority patent/DK1473040T3/da
Priority to ES98929965T priority patent/ES2229511T3/es
Priority to DE69826132T priority patent/DE69826132T2/de
Priority to EP98929965A priority patent/EP1001802B1/de
Priority to HK00107524A priority patent/HK1029738A1/xx
Priority to US09/942,661 priority patent/US20020002135A1/en
Priority to US10/389,797 priority patent/US7018982B2/en
Priority to HK05103473.5A priority patent/HK1070816A1/xx
Priority to US11/305,339 priority patent/US7507715B2/en
Priority to US12/351,558 priority patent/US7749543B2/en
Priority to JP2010000066A priority patent/JP5525825B2/ja
Priority to CY20101100091T priority patent/CY1110287T1/el
Priority to US12/822,089 priority patent/US8153588B2/en
Priority to US13/405,093 priority patent/US8765674B2/en
Priority to JP2013206919A priority patent/JP2014015479A/ja
Priority to US14/285,437 priority patent/US20140256632A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SE9702401A 1997-06-19 1997-06-19 Pharmaceutical use SE9702401D0 (sv)

Priority Applications (32)

Application Number Priority Date Filing Date Title
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use
CA2294101A CA2294101C (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
PCT/SE1998/001095 WO1998057656A1 (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
ES98929965T ES2229511T3 (es) 1997-06-19 1998-06-08 Preparacion farmaceutica combinada que comprende una hormona paratiroidea y un inhibidor de la resorcion osea.
JP50425999A JP4989811B2 (ja) 1997-06-19 1998-06-08 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
DK98929965T DK1001802T3 (da) 1997-06-19 1998-06-08 Farmaceutisk kombinationspræparat af parathyroidhormon og en knogleresorptionsinhibitor
EP04017622A EP1473040B1 (de) 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon
ZA984947A ZA984947B (en) 1997-06-19 1998-06-08 Pharmaceutical use
PT04017622T PT1473040E (pt) 1997-06-19 1998-06-08 Utilização de hormona paratiróide humana
AU79458/98A AU753477B2 (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
CA2698626A CA2698626C (en) 1997-06-19 1998-06-08 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
PT98929965T PT1001802E (pt) 1997-06-19 1998-06-08 Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
AT04017622T ATE447410T1 (de) 1997-06-19 1998-06-08 Verwendung von humanem parathyroid-hormon
US09/125,247 US6284730B1 (en) 1997-06-19 1998-06-08 Methods useful in the treatment of bone resorption diseases
DE69841279T DE69841279D1 (de) 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon
AT98929965T ATE275419T1 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
ES04017622T ES2335404T3 (es) 1997-06-19 1998-06-08 Utilizacion de la hormona paratiroidea humana.
EP98929965A EP1001802B1 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
DK04017622.4T DK1473040T3 (da) 1997-06-19 1998-06-08 Anvendelse af humant parathyroidhormon
DE69826132T DE69826132T2 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
HK00107524A HK1029738A1 (en) 1997-06-19 2000-11-23 A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor.
US09/942,661 US20020002135A1 (en) 1997-06-19 2001-08-31 Pharmaceutical use
US10/389,797 US7018982B2 (en) 1997-06-19 2003-03-18 Methods useful in the treatment of bone resorption diseases
HK05103473.5A HK1070816A1 (en) 1997-06-19 2005-04-22 Use of human parathyroid hormone
US11/305,339 US7507715B2 (en) 1997-06-19 2005-12-19 Methods useful in the treatment of bone resorption diseases
US12/351,558 US7749543B2 (en) 1997-06-19 2009-01-09 Methods useful in the treatment of bone resorption diseases
JP2010000066A JP5525825B2 (ja) 1997-06-19 2010-01-04 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
CY20101100091T CY1110287T1 (el) 1997-06-19 2010-01-29 Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
US12/822,089 US8153588B2 (en) 1997-06-19 2010-06-23 Methods useful in the treatment of bone resorption diseases
US13/405,093 US8765674B2 (en) 1997-06-19 2012-02-24 Methods useful in the treatment of bone resorption diseases
JP2013206919A JP2014015479A (ja) 1997-06-19 2013-10-02 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤
US14/285,437 US20140256632A1 (en) 1997-06-19 2014-05-22 Methods useful in the treatment of bone resorption diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use

Publications (1)

Publication Number Publication Date
SE9702401D0 true SE9702401D0 (sv) 1997-06-19

Family

ID=20407482

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use

Country Status (15)

Country Link
US (8) US6284730B1 (de)
EP (2) EP1473040B1 (de)
JP (3) JP4989811B2 (de)
AT (2) ATE275419T1 (de)
AU (1) AU753477B2 (de)
CA (2) CA2294101C (de)
CY (1) CY1110287T1 (de)
DE (2) DE69841279D1 (de)
DK (2) DK1001802T3 (de)
ES (2) ES2335404T3 (de)
HK (2) HK1029738A1 (de)
PT (2) PT1001802E (de)
SE (1) SE9702401D0 (de)
WO (1) WO1998057656A1 (de)
ZA (1) ZA984947B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
PT1397156E (pt) 2001-06-01 2007-05-31 Novartis Ag Método para a administração oral da hormona paratireóide ( pth ).
AU2002361545B2 (en) * 2001-06-28 2007-03-15 Microchips, Inc. Methods for hermetically sealing microchip reservoir devices
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
US20050119183A1 (en) * 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
WO2006081279A2 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
EP1896134A2 (de) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung degenerativer knochenerkrankungen
PT1734251E (pt) * 2005-06-17 2007-03-30 Magneti Marelli Powertrain Spa Injector de combustível
JP2009515535A (ja) * 2005-11-10 2009-04-16 ボード オブ コントロール オブ ミシガン テクノロジカル ユニヴァーシティー クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
KR20170089018A (ko) * 2009-09-09 2017-08-02 아사히 가세이 파마 가부시키가이샤 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제
EP2509996A1 (de) 2009-12-07 2012-10-17 Michigan Technological University Schwarzbär-parathyroid-hormon und verfahren zur verwendung des schwarzbär-parathyroid-hormons
DK2790710T3 (da) * 2011-12-13 2020-11-30 Amorphical Ltd Amorft calciumcarbonat til behandling af calciummalabsorption og metaboliske knoglelidelser
DK3265115T3 (da) * 2015-03-03 2022-09-05 Radius Health Inc Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud
RU2748976C2 (ru) 2015-06-04 2021-06-02 Аморфикал Лтд. Композиции аморфного карбоната кальция для ингаляции, подъязычного или трансбуккального введения
WO2018078616A1 (en) 2016-10-25 2018-05-03 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3768177A (en) 1972-08-02 1973-10-30 R Thomas Educational device
US3886132A (en) 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4468464A (en) 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4016314A (en) 1975-06-26 1977-04-05 Hallco Inc. Embroidered fruit bowl wall hanging and kit for making same
US4264731A (en) 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4199060A (en) 1978-07-20 1980-04-22 Howard Hardware Products, Inc. Lock installation kit
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4383066A (en) 1980-04-15 1983-05-10 Mitsubishi Gas Chemical Company, Inc. Polyphenylene ether resin composition
JPS5825439B2 (ja) 1980-12-30 1983-05-27 株式会社林原生物化学研究所 ヒト副甲状腺ホルモンの製造方法
US4394443A (en) 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4624926A (en) 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
NO163060C (no) 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
US4385212A (en) 1981-10-05 1983-05-24 Bell Telephone Laboratories Incorporated Expandable communication terminal housing
US4424278A (en) 1981-11-16 1984-01-03 Research Corporation Cancer detection procedure using an acyl carrier protein
US4532207A (en) 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4595658A (en) 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
WO1984001173A1 (en) 1982-09-15 1984-03-29 Immuno Nuclear Corp Production of mature proteins in transformed yeast
DE3312928A1 (de) 1983-04-11 1984-11-22 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Human-parathormon produzierende hybridvektoren und human-parathormongen
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
US4637980A (en) 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
EP0177343B1 (de) 1984-10-05 1992-07-22 Genentech, Inc. DNA, Zellkulturen und Verfahren zur Sekretion von heterologen Proteinen und periplasmische Proteinrückgewinnung
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
HU204563B (en) 1984-12-06 1992-01-28 Synergen Biolog Inc Process for producing recombinant serine-protease inhibitors and dns sequencyes for them
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IE67035B1 (en) 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US5420242A (en) 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US5010010A (en) 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
EP0329693A4 (de) 1986-10-30 1989-09-26 Synergen Biolog Inc Menschliche pankreas-sekretions-trypsin-inhibitoren, hergestellt mit dns-rekombinationsmethoden und verfahren für ihre herstellung.
FI77278C (fi) 1986-10-31 1989-02-10 Ahlstroem Oy Foerfarande och anordning foer foerbraenning av sodasvartlut.
US4833125A (en) 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
FR2618914B1 (fr) 1987-07-31 1991-12-06 Alain Souloumiac Perfectionnements apportes aux interrupteurs optomagnetiques
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
IL88344A (en) 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223407A (en) 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5171670A (en) 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
USRE37919E1 (en) 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
DE69125394T2 (de) 1990-11-26 1997-08-21 Robert R. Omaha Nebr. Recker Behandlung von osteoporose unter verwendung von wachstumshormon-freisetzendem faktor (grf) in verbindung mit parathyroidhormon (pth)
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
WO1993011785A1 (en) 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
SK74594A3 (en) 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
TW303299B (de) 1993-07-22 1997-04-21 Lilly Co Eli
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
AU686458B2 (en) * 1994-09-09 1998-02-05 Procter & Gamble Company, The Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
CA2199250A1 (en) 1994-09-09 1996-03-14 John Althorp Bevan Estrogens and parathyroid hormone for treating osteoporosis
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5550134A (en) 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use

Also Published As

Publication number Publication date
WO1998057656A1 (en) 1998-12-23
JP4989811B2 (ja) 2012-08-01
EP1473040A1 (de) 2004-11-03
JP5525825B2 (ja) 2014-06-18
US20020002135A1 (en) 2002-01-03
JP2010100644A (ja) 2010-05-06
CA2294101A1 (en) 1998-12-23
HK1070816A1 (en) 2005-06-30
HK1029738A1 (en) 2001-04-12
CY1110287T1 (el) 2015-01-14
ES2335404T3 (es) 2010-03-26
US20140256632A1 (en) 2014-09-11
US20090118192A1 (en) 2009-05-07
US20110071081A1 (en) 2011-03-24
AU7945898A (en) 1999-01-04
DK1001802T3 (da) 2005-01-17
EP1001802B1 (de) 2004-09-08
ATE275419T1 (de) 2004-09-15
US7507715B2 (en) 2009-03-24
PT1001802E (pt) 2005-01-31
CA2698626C (en) 2016-02-09
DE69826132D1 (de) 2004-10-14
EP1001802A1 (de) 2000-05-24
ATE447410T1 (de) 2009-11-15
ZA984947B (en) 1999-01-04
DE69826132T2 (de) 2005-09-15
EP1473040B1 (de) 2009-11-04
CA2294101C (en) 2010-08-03
US20060211613A1 (en) 2006-09-21
ES2229511T3 (es) 2005-04-16
PT1473040E (pt) 2010-02-02
AU753477B2 (en) 2002-10-17
US8153588B2 (en) 2012-04-10
US20120148684A1 (en) 2012-06-14
US8765674B2 (en) 2014-07-01
JP2014015479A (ja) 2014-01-30
US7018982B2 (en) 2006-03-28
CA2698626A1 (en) 1998-12-23
DK1473040T3 (da) 2010-03-15
US20030162716A1 (en) 2003-08-28
US7749543B2 (en) 2010-07-06
JP2002504140A (ja) 2002-02-05
US6284730B1 (en) 2001-09-04
DE69841279D1 (de) 2009-12-17

Similar Documents

Publication Publication Date Title
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
EP1064000A4 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
MX171191B (es) Composiciones farmaceuticas de glipizida
BR9906796A (pt) Método para a administração de análogos de insulina monoméricos
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
GEP20043314B (en) Pharmaceutical Composition Comprising Entacapone, Levodopa, and Carbidopa
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ES2010561A6 (es) Procedimiento para preparar una composicion farmaceutica a base de un analogo de somatostatina.
EP0911331A3 (de) Substutierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen, und Anwendungsmethoden
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
DE60028559D1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen